image
Ovid Therapeutics Inc. OVID
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.2978
-5.87 %
$ 21.2 M
Market Cap
-0.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one OVID stock under the worst case scenario is HIDDEN Compared to the current market price of 0.298 USD, Ovid Therapeutics Inc. is HIDDEN

OVID Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one OVID stock under the base case scenario is HIDDEN Compared to the current market price of 0.298 USD, Ovid Therapeutics Inc. is HIDDEN

OVID Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one OVID stock under the best case scenario is HIDDEN Compared to the current market price of 0.298 USD, Ovid Therapeutics Inc. is HIDDEN

OVID Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart OVID

image
1M 3%
6M -256%
1Y -954.0%
3Y -592%
5Y -1609%
All
$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.215 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
566 K REVENUE
44.50%
Growth Rates
1Year 44.50%
3Years -86.05%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-61.9 M OPERATING INCOME
-4.39%
Growth Rates
1Year -4.39%
3Years -14.43%
5Years -0.15%
7Years 0.70%
10Years -63.73%
-26.4 M NET INCOME
49.50%
Growth Rates
1Year 49.50%
3Years -6.71%
5Years 15.25%
7Years 12.02%
10Years -50.38%
-56 M OPERATING CASH FLOW
-22.23%
Growth Rates
1Year -22.23%
3Years -13.75%
5Years -1.84%
7Years -8.57%
10Years -71.03%
54.6 M INVESTING CASH FLOW
2215.55%
Growth Rates
1Year 2215.55%
3Years 217.39%
5Years 30.72%
7Years 173.82%
10Years 148.36%
622 K FINANCING CASH FLOW
-97.96%
Growth Rates
1Year -97.96%
3Years -11.72%
5Years -62.73%
7Years -48.72%
10Years -21.19%
76 K REVENUE
-56.07%
Growth Rates
1Year 44.50%
3Years -86.05%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-10.7 M OPERATING INCOME
18.93%
Growth Rates
1Year -4.39%
3Years -14.43%
5Years -0.15%
7Years 0.70%
10Years -63.73%
-9.25 M NET INCOME
33.94%
Growth Rates
1Year 49.50%
3Years -6.71%
5Years 15.25%
7Years 12.02%
10Years -50.38%
-10 M OPERATING CASH FLOW
33.31%
Growth Rates
1Year -22.23%
3Years -13.75%
5Years -1.84%
7Years -8.57%
10Years -71.03%
21.3 M INVESTING CASH FLOW
7191.78%
Growth Rates
1Year 2215.55%
3Years 217.39%
5Years 30.72%
7Years 173.82%
10Years 148.36%
0 FINANCING CASH FLOW
0.00%
Growth Rates
1Year -97.96%
3Years -11.72%
5Years -62.73%
7Years -48.72%
10Years -21.19%
Balance Sheet Ovid Therapeutics Inc.
image
Current Assets 55.9 M
Cash & Short-Term Investments 53.1 M
Receivables 0
Other Current Assets 2.86 M
Non-Current Assets 36.2 M
Long-Term Investments 21 M
PP&E 13.2 M
Other Non-Current Assets 2.02 M
57.59 %3.11 %22.76 %14.35 %Total Assets$92.2m
Current Liabilities 10.5 M
Accounts Payable 3.19 M
Short-Term Debt 1.34 M
Other Current Liabilities 6 M
Non-Current Liabilities 13.4 M
Long-Term Debt 0
Other Non-Current Liabilities 13.4 M
13.33 %5.58 %25.04 %56.05 %Total Liabilities$23.9m
EFFICIENCY
Earnings Waterfall Ovid Therapeutics Inc.
image
Revenue 566 K
Cost Of Revenue 600 K
Gross Profit -34 K
Operating Expenses 62.5 M
Operating Income -61.9 M
Other Expenses -35.5 M
Net Income -26.4 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)566k(600k)(34k)(62m)(62m)35m(26m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-6.01% GROSS MARGIN
-6.01%
Averages
1Year -6.01%
3Years 34.02%
5Years 60.41%
7Years 43.15%
10Years 30.21%
-10933.75% OPERATING MARGIN
-10933.75%
Averages
1Year -10933.75%
3Years -9921.59%
5Years -6070.11%
7Years -4335.80%
10Years -3035.06%
-4670.14% NET MARGIN
-4670.14%
Averages
1Year -4670.14%
3Years -7151.09%
5Years -4406.83%
7Years -3147.74%
10Years -2203.41%
-38.74% ROE
-38.74%
Averages
1Year -38.74%
3Years -45.74%
5Years -50.78%
7Years -67.50%
10Years -61.50%
-28.68% ROA
-28.68%
Averages
1Year -28.68%
3Years -32.71%
5Years -28.26%
7Years -46.24%
10Years -45.71%
-74.58% ROIC
-74.58%
Averages
1Year -74.58%
3Years -51.44%
5Years -47.31%
7Years -65.87%
10Years -60.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ovid Therapeutics Inc.
image
120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -26.4 M
Depreciation & Amortization 613 K
Capital Expenditures -71 K
Stock-Based Compensation 6.28 M
Change in Working Capital -150 K
Others -35.9 M
Free Cash Flow -56 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ovid Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for OVID of $6.25 , with forecasts ranging from a low of $3 to a high of $11 .
OVID Lowest Price Target Wall Street Target
3 USD 907.39%
OVID Average Price Target Wall Street Target
6.25 USD 1998.72%
OVID Highest Price Target Wall Street Target
11 USD 3593.75%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Ovid Therapeutics Inc.
image
Sold
0-3 MONTHS
5.14 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
4.97 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago. zacks.com - 2 months ago
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability OV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025 Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of 2026 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024. globenewswire.com - 2 months ago
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. globenewswire.com - 2 months ago
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. globenewswire.com - 2 months ago
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. globenewswire.com - 3 months ago
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. zacks.com - 6 months ago
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy. globenewswire.com - 8 months ago
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 8 months ago
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 9 months ago
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 9 months ago
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 9 months ago
8. Profile Summary

Ovid Therapeutics Inc. OVID

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 21.2 M
Dividend Yield 0.00%
Description Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Contact 1460 Broadway, New York, NY, 10036 https://www.ovidrx.com
IPO Date May 5, 2017
Employees 23
Officers Dr. Dirk Haasner Senior Vice President of Global Manufacturing & CMC QA Mr. Zhong Zhong Ph.D. Chief Scientific Officer Mr. Tom Parry Vice President of Research and Early Development Dr. Julia Tsai Ph.D. Senior Vice President of Clinical Development Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. Chief Executive Officer & Chairman Ms. Margaret Alexander President & Chief Operating Officer Dr. Manal Morsy M.B.A., M.D., PH.D. Chief Regulatory Officer Dr. Toshiya Nishi D.V.M. Head of Epilepsy Research Ms. Victoria Fort Senior Vice President of Corporate Affairs & Corporate Strategy Mr. Jeffrey A. Rona Chief Business and Financial Officer